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Abstract
Clostridioides difficile is an opportunistic enteric pathogen that can cause a range of
symptoms in humans from diarrhea to pseudomembranous colitis. The risk of recurrence of C.
difficile infection after initial treatment with antibiotics is high. Although prior studies have
sought to understand the link between the human gut microbiome and the risk of recurrence,
none have utilized shotgun metagenomic sequencing methods to establish a relationship between
microbiota diversity and recurrence risk. In this study, stool samples were obtained from 47
patients at Yale New Haven Hospital who tested positive for an incident C. difficile infection.
Shotgun metagenomic sequencing was used to characterize the abundance and diversity of the
microbiota and the antibiotic resistome of each sample. The association between taxonomic
diversity of the gastrointestinal microbiota and the risk for recurrence, case definition, and
patient characteristics was analyzed. There was a significant association between age and the risk
for recurrent infection, with older patients more likely to experience recurrence. Linear
discriminant analysis effect size revealed that certain taxonomic groups were differentially
prevalent in patients with and without a recurrent episode and in patients with communityacquired infections vs. those with hospital- or healthcare-associated infections. Those who
experienced a recurrent infection had a higher abundance of Blautia producta, and a lower of
abundance of Gardnerella vaginalis and Eggerthella lenta than patients who did not experience
a recurrence. The microbiota of patients who had a community-acquired infection were more
likely to include protective bacterial species and bacteriophage, such as Bacteroides,
Faecalibacterium prausnitzii, and crAssphage. This study provides a preliminary exploration
into the association between the human microbiome and the risk of C. difficile recurrence and
demonstrates the value of using shotgun metagenomic sequencing for further investigation.
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Tables and Figures
Table 1. Description of the sample, by CDI recurrence.a
Recurrence
Characteristic
Yes (N = 7)
No (N = 35)
pb
Age (years)
75.1 ± 12.9
54.9 ± 24.1
0.03
Sex
Male
3 (42.9)
17 (48.6)
1.00
Female
4 (57.1)
18 (51.4)
Case Definition
0.73
Hospital-acquired
2 (28.6)
11 (31.4)
Healthcare- associated
5 (71.4)
18 (51.4)
Community-acquired
0 (0.0)
5 (17.1)
Chronic Kidney Disease
0.16
Yes
3 (42.9)
6 (17.1)
No
4 (57.1)
29 (82.7)
Congestive Heart Failure
0.19
Yes
2 (28.6)
3 (8.6)
No
5 (71.4)
32 (91.4)
Stroke
0.53
Yes
1 (14.3)
3 (8.6)
No
6 (85.7)
32 (91.4)
Diabetes mellitus
0.11
Yes
3 (42.9)
5 (14.3)
No
4 (57.1)
30 (85.7)
Antibiotic use ≤ 12 weeks before
incident CDI
1.00
Yes
6 (85.7)
28 (80.0)
No
1 (14.3)
5 (14.3)
Unknown
0 (0.0)
2 (5.7)
H2 blocker use ≤ 12 weeks
before incident CDI
1.00
Yes
3 (42.9)
17 (48.6)
No
4 (57.1)
17 (48.6)
Unknown
0 (0.0)
1 (2.9)
Proton pump inhibitor use ≤ 12
weeks before incident CDI
0.53
Yes
2 (28.6)
16 (45.7)
No
5 (71.4)
18 (51.4)
Unknown
0 (0.0)
1 (2.9)
a
Table values are mean ± SD for continuous variable and n (column %) for categorical variables.
b
P-value is for Duncan’s MRT (continuous variable) or Fisher’s Exact test (categorical variables).
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Figure 1. Heatmap of the most abundant antibiotic resistance genes in stool samples from 42 patients. The color
keys for recurrence status and case definition are indicated on the left. Abbreviation: MLS, macrolide-lincosamidestreptogramin.
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Figure 2. Linear discriminant analysis effect size scores for comparisons between relative abundance of antibiotic
resistance genes among 47 patients based on case definition. A. Hospital-acquired infections vs. communityacquired infections. B. Healthcare-associated infections vs. community-acquired infections. Abbreviation: LDA,
linear discriminant analysis.
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Figure 3. Linear discriminant analysis effect size scores for comparisons between relative abundance of taxa among
42 patients with or without a recurrent infection. Abbreviation: LDA, linear discriminant analysis.
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Figure 4. Linear discriminant analysis effect size scores for comparisons between relative abundance of taxa among
47 patients based on case definition. A. Hospital-acquired infections (1) vs. healthcare-associated infections (2). B.
Hospital-acquired infections (1) vs. community-acquired infections (3). C. Healthcare-associated infections (2, not
shown) vs. community-acquired infections (3). Abbreviation: LDA, linear discriminant analysis.
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Introduction
Clostridioides difficile is a gram-positive, spore-forming bacillus that causes diarrhea and
colitis in susceptible individuals. It is a major cause of healthcare-associated infections in the
United States, with upwards of half a million infections and nearly 30,000 associated deaths
every year.1 Up to 20% of all individuals who are infected with C. difficile experience a
recurrence in infection within twelve weeks of treatment.2 As such, C. difficile places a large
burden on the US healthcare system, costing nearly $1.5 billion total annually.3 Although
initially considered to be a primarily nosocomial or healthcare-associated infection, communityacquired C. difficile infections (CDIs) have become an increasing problem, especially among
populations previously thought to be at low risk for infection.4
C. difficile is resistant to a wide array of commonly used antibiotics, including penicillin,
cephalosporins, clindamycin, tetracyclines, and fluoroquinolones.5 Thus, it is an opportunistic
pathogen that takes advantage of disturbances in the normal human gut microflora to proliferate
and cause disease in human hosts.6 One of the major risk factors for CDI, therefore, is repeated
or sustained antibiotic usage.7 Other known risk factors for infection are overnight stays in
hospitals and long-term care facilities, advanced age, underlying medical problems, reduction of
stomach acid through proton pump inhibitors, and the use of immunosuppressants.8-10 The risk
factors for recurrent infection are similar to that of incident infection and include increasing age
and the severity of primary infection.11
Understanding the role of the gut microbiome in C. difficile infection is essential to
understanding the risk factors for infection and developing targets for infection prevention and
treatment. Certain bacterial species in the human gut microbiome have been shown to be
associated with resistance to colonization by C. difficile, specifically members within
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Ruminococcaceae, Lachnospiraceae, Bacteroides, and Porphyromonadaceae.12 Infection with C.
difficile has also been associated with a higher abundance and lower diversity of bacteriophage
Caudovirales.13 A metagenomic analysis of CDI-infected elderly patients in a hospital setting
revealed that C. difficile infection was associated with a lower gut microbial diversity, as well as
a lower incidence of commensal microbes and a higher incidence of opportunistic pathogens.14
Furthermore, studies in infants suggest that a machine learning approach can be used to identify
antibiotic resistance genes within the gut that can predict the effect of antibiotics on the gut
microflora, a tool that could be utilized for predicting treatment outcomes for CDI.15
The association between the human gut microbiome and the risk of CDI recurrence has
been explored using 16S rRNA gene sequencing. One such study found that patients who
experienced a recurrent episode had elevated levels of Veillonella, Enterobacteriaceae,
Streptococcus, Parabacteroides and Lachnospiraceae.16 Although the link between the human
microbiome and CDI risk has been investigated in previous studies, shotgun metagenomic
sequencing has not yet been used to determine the relationship between the human gut
microbiome and antibiotic resistome and the risk for CDI recurrence.
The goal of this study was to use shotgun metagenomic sequencing methods to determine
the association between the risk of recurrence and the following factors: the abundance and
diversity of specific bacterial taxa within the gut microbiome, and the presence of antibiotic
resistance genes.
Methods
Yale University’s institutional review board approved this study. Stool samples were
obtained through collaboration with Connecticut’s Emerging Infections Program, which is
responsible for C. difficile surveillance within the New Haven catchment area. From April 26,
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2019 to December 19, 2019, a total of 47 stool samples were collected from patients at Yale New
Haven Hospital who tested positive for an incident C. difficile infection. A case was defined as
incident if the individual was not treated for CDI in the twelve weeks prior to the date of stool
collection. A medical chart review was conducted for each individual to identify possible risk
factors for infection, including past medical history, antibiotic use, use of proton pump
inhibitors, H2 blockers, and other immunosuppressants, as well as details on CDI treatment and
recent contact with healthcare.
Individuals were classified based on recurrence status and case definition. A case was
defined as recurrent if an individual experienced a second CDI within 2-12 weeks after incident
infection. Any infection after this time period was considered a re-infection and not counted
among the recurrent cases. Additionally, all CDIs included in the study were classified into one
of three case definition groups: hospital-acquired infections, healthcare-associated community
onset infections, and community-acquired infections. An infection was considered to be hospitalacquired if the incident stool sample was collected at least 3 days after admission to a hospital. In
contrast, an infection was considered to be healthcare-associated community onset if the incident
stool sample was collected less than 3 days after admission to a hospital and/or the patient had
any of the following encounters with health care within 12 weeks of the date of the incident stool
sample collection: visited a hospital emergency department, received surgery or dialysis
treatment, or was admitted to a hospital. A patient’s CDI was considered community-acquired if
they did have any health care encounters within 12 weeks prior to the incident stool sample
collection and/or their stool sample was collected less than 3 days after admission to a hospital.
Microbial DNA was extracted from stool samples using the PureLink Microbiome
Purification Kit (Invitrogen). After DNA quantification using the Quant-iT Assay Kit
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(Invitrogen), samples were prepared for sequencing using the NEBNext Ultra II FS DNA Library
Prep Kit for Illumina (New England Biolabs). Shotgun metagenomic sequencing was carried out
on an Illumina HiSeq4000 at the Yale Center for Genome Analysis, after which taxonomic
identification of bacteria and bacteriophage was carried out. Taxonomic labels were assigned to
DNA sequences using Kraken, and species abundance was estimated using Bracken.17,18
Antibiotic resistance genes (ARGs) were identified and quantified using ARGs-OAP v2.0.19
ARG copy numbers were normalized against reference sequence lengths and then against
prokaryotic cell number, and were grouped into the following ARG types based on mechanism
of resistance: aminoglycoside, bacitracin, beta-lactam, bleomycin, chloramphenicol, fosfomycin,
fosmidomycin, kasugamycin, macrolide-lincosamide-streptogramin, polymyxin, quinolone,
rifamycin, sulfonamide, tetracycline, trimethoprim, vancomycin, and multidrug.
After the microbiome and antibiotic resistome for each sample were characterized,
statistical methods were used to determine the unadjusted associations between case definition or
the risk for recurrence and the following variables: age, sex at birth, underlying medical
conditions, and the use of antibiotics, H2 blockers, and proton pump inhibitors prior to incident
infection. Due to the low sample size, categorical variables were analyzed using Fisher’s Exact
test. Age was analyzed using Duncan’s new multiple range test or one-way analysis of variance
(ANOVA) as appropriate. All analyses were carried out using SAS v9.4.
Linear discriminant analysis effect size (LefSe) was used to identify differences in the
presence and abundance of antibiotic resistance genes in patients who experienced a recurrent
episode and those who did not. LefSe was also used to compare differences between the three
case definitions by analyzing each pair of categories separately: community-acquired vs. hospital
acquired, community-acquired vs. healthcare-associated, and hospital-acquired vs. healthcare-
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associated. An alpha value of 0.1 and a threshold on the logarithmic linear discriminant analysis
(LDA) score for discriminative features of 2.0 were used.
LefSe was also used to compare the taxonomic diversity between patients with and
without a recurrent episode and between case definitions. Before analysis, the proportion of total
sequencing reads was recalculated for each species in each sample after the removal of human
DNA. The proportion of sequencing reads for each taxonomic group was summed across all
samples, and the top 65 taxa with the highest total relative abundance were selected for analysis.
The combined dataset was restricted to these 65 species while the rest of the taxonomic groups
were collapsed into a single category for each sample. An alpha value of 0.1 and the and a
threshold on the LDA score for discriminative features of 2.0 were used.
Results
A total of 47 stool samples were obtained for metagenomic analysis. Out of the 47
individuals who provided a stool sample, 25 were male and 22 were female, with ages ranging
from 3 to 95. Of the total, 16 infections were classified as hospital-acquired, 25 were classified
as healthcare-associated community onset, and 6 were community-acquired. Five of the
individuals in the study died before the period during which a recurrent C. difficile episode may
have occurred. These subjects were excluded from all analyses that used recurrence as a
dependent variable. The resulting sample of 42 individuals included 20 males and 22 females. Of
this sample, 7 individuals experienced a recurrent episode 2-12 weeks after incident infection.
The majority of individuals had underlying medical conditions prior to their incident C.
difficile infections. The most common medical conditions were chronic kidney disease (n=11),
diabetes mellitus (n=9), congestive heart failure (n=7), recent solid organ transplants (n=7), and
hematologic malignancies (n=7). Frequency of medication use within 12 weeks of the incident
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positive stool sample was also fairly high; 20 subjects took proton pump inhibitors, 21 took H2
blockers, while 29 took some other type of immunosuppressive therapy, such as steroids and/or
chemotherapy. Antimicrobial therapy within the 12 weeks of incident stool collection was
extremely common; 39 individuals were prescribed at least one antibiotic during that time
period. The most common antibiotics were piperacillin/tazobactam (n=13), vancomycin (n=12),
ciprofloxacin (n=11), ceftriaxone (n=11), and metronidazole (n=8). Cephalosporins were the
most commonly administered class of antibiotics (n=21), followed by penicillins (n=20), and
fluoroquinolones (n=14).
Age was found to be significantly associated with the risk for recurrence. Older people
were more likely to experience a recurrent episode than younger people (p=0.038; Table 1). No
other significant associations were observed between recurrence and other exposures of interest,
including case definition, comorbidities, antibiotic use, and H2 blocker and proton pump
inhibitor use. There were also no significant associations between these variables and case
definition.
Hierarchical clustering was used to group samples by the abundance of antibiotic
resistance genes (Figure 1). Samples did not cluster based on recurrence or case definition.
However, LefSe indicated that genes that conferred resistance to fosfomycin were more
abundant in patients who experienced hospital-acquired infections compared to those who
experienced a community-acquired infection (Figure 2a). Additionally, bacitracin and
sulfonamide resistance genes were more abundant in healthcare-associated community-onset
infections than in community-acquired infections (Figure 2b). There were no significant
differences in the abundance of ARGs between hospital-acquired and healthcare-associated
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infections. Similarly, no differences were observed in the abundance of ARGs between patients
who did and did not experience a recurrent infection.
A total of 6059 bacterial taxa and bacteriophage were identified in stool samples from 47
patients. LefSe identified certain taxa as differentially abundant depending on a patient’s
recurrence status. Patients who experienced a recurrent infection had a higher abundance of
Blautia producta and a lower of abundance of Gardnerella vaginalis and Eggerthella lenta than
patients who did not experience a recurrence (Figure 3). Differences in taxonomic abundance
were also observed between case definitions. Compared to healthcare-associated infections,
hospital-acquired infections had a higher abundance of Actinomyces pacaensis, Veillonella
dispar, and Streptococcus salivarius, and lower abundance of B. producta, Erysipelotrichaceae,
and Enterococcus faecalis (Figure 4a). In comparison to community-acquired infections,
hospital-acquired infections had a higher abundance of Bifidobacterium longum and Collinsella
aerofasciens, and a lower abundance of Bacteroides vulgatus, Bacteroides fragilis,
Faecalibacterium prausnitzii, Alistipes finegoldii, and crAssphage (Figure 4b). Finally, patients
with community-acquired infections had a higher abundance of B. vulgatus, Bacteroides
helcogenes, and B. fragilis than patients with healthcare-associated infections (Figure 4c).
Discussion
The results from this study provide preliminary evidence that the risk of recurrence of C.
difficile infection is associated with the diversity and composition of the human gut microbiome.
Metagenomic analysis of stool samples from 42 patients suggests that B. producta is associated
with the risk of recurrence. This finding is somewhat surprising because Blautia is a commensal
genus that has been shown to be underrepresented in C. difficile-positive stool samples.20 In one
study, B. producta was used with a cocktail of nine other bacterial species to successfully treat
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chronic CDI in five patients.21 All of the patients in this study, however, were already colonized
with B. producta prior to treatment, making it unlikely that B. producta alone was responsible for
clearing the recurrent infections. Risk of recurrence was also negatively associated with E. lenta,
which is part of the normal human gut microflora and can cause ulcerative colitis in humans.22
Similarly to C. difficile, antibiotic treatment has been shown to increase the amount of E. lenta in
the human gut microbiome.22,23 The results from the current study suggest that the relationship
between recurrent CDI and certain commensal microorganisms is more complex than originally
assumed and warrants further investigation.
Bacterial taxonomic groups also differed in relative abundance between case definitions.
A major result was that the microbiomes of patients with community-acquired infections were
more likely to contain taxa that are associated with healthy human gut microflora. Communityacquired infections had a higher abundance of species in the genus Bacteroides, including B.
fragilis, B. vulgatus, and B. helcogenes. Bacteroides species are commensal microorganisms that
operate in the healthy human gastrointestinal tract.24 One study showed that patients with CDI
were deficient in Bacteroides, while healthy controls maintained relatively high levels of species
from this genus. Compared to hospital-acquired infections, community-acquired infections were
also associated with higher levels of F. prausnitzii and crAssphage. F. prausnitzii is a member of
Ruminococcaceae and is the most abundant species found in a healthy human gut microbiome.25
CrAssphage, a lytic phage that targets Bacteroides, is one of the most commonly found
bacteriophages in the human gut.26 Studies that sought to establish the association between
bacteriophages and recurrent CDI risk and treatment found that individuals that suffer from
recurrent CDI have lower levels of crAssphage than healthy fecal transplant donors.27
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The abundance of healthy commensal bacteria and bacteriophage in patients with
community-acquired infections may be due to a number of reasons. First, community-acquired
infections are usually less severe than hospital-acquired infections,4 which may indicate that the
healthy gut microbiome is not as severely disturbed in these infections. Second, these patients
have had little to no contact with health care leading up to their CDI and are more likely to be
healthier than patients that have had extended hospital stays or repeated exposures to health care
settings. This may also account for the differential expression of certain antibiotic resistance
genes in patients with CDI. The microbiome of patients with hospital-acquired and healthcareassociated infections were more likely to express genes resistant to fosfomycin or bacitracin and
sulfonamide, respectively. Research has shown that ambulatory and hospitalized patients harbor
a high prevalence of antibiotic resistant organisms, regardless of whether they actually took
antibiotics.28
Although there was a positive association between age and the risk for recurrence, the
data from this study did not reveal any other associations between recurrence risk and other
known factors for recurrence, including use of antibiotics and proton pump inhibitors.2,29 Failure
to find significant associations between these variables may be due to the small sample size,
which was a major limitation to this study. Stool samples were obtained from the Connecticut
Emerging Infections Program, which is responsible for sending positive C. difficile stool samples
to the CDC as part of a nationwide surveillance program. The sample size was therefore limited
by the number of positive samples that were available for metagenomic analysis. Due to the
prospective study design, individuals were enrolled in the study before we knew whether or not
they would experience a recurrent infection. This, in keeping with the estimate that
approximately 20% of all positive C. difficile cases eventually experience a recurrent infection,
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resulted in the number of recurrent cases in the study to be limited to only 7 samples.
Consequently, many of the statistical analyses performed in this study were underpowered.
Future studies that seek to explore the association between the gut microbiome and the risk for
recurrent CDI should aim to increase the overall sample size.
Potential missing and incomplete medical histories for the subjects enrolled in the study
was another major limitation. The majority of stool samples included in the analysis were from
individuals who lived outside the New Haven catchment area. Three subjects’ primary addresses
were outside of Connecticut, while one subject moved out of state soon after their positive
diagnosis. It is possible that individuals living outside of the New Haven catchment area received
medical care from providers not in the Yale New Haven Health System (YNHHS). If so, it is not
guaranteed that these medical visits were documented within the YNHHS Epic interface, and
they may have been omitted during chart review. Consequently, information about patients’
medical histories, including administered antibiotics and comorbidities, may have been
incomplete.
This study offers a preliminary analysis of the association between the risk of recurrence
of Clostridioides difficile infection and the human gut microbiome and resistome. Increasing our
understanding of the factors that influence the risk of recurrence can aid in future efforts to
identify individuals with CDI who are most likely to go on and experience a recurrent episode, as
well as inform possible treatment strategies for patients for whom standard antibiotic therapies
are ineffective in clearing infection. Whole genome sequencing provides unique insights into the
relationship between CDI and the human microbiome and antibiotic resistome that is not
provided by traditional sequencing methods. This pilot study may operate as a stepping stone for
future metagenomic investigations into the human microbiome and the risk of CDI recurrence.
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